Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

@article{Druker2006FiveyearFO,
  title={Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.},
  author={Brian J. Druker and François Guilhot and Stephen G. O’Brien and Insa Gathmann and Hagop M. Kantarjian and Norbert Gattermann and Michael W N Deininger and Richard T. Silver and John M. Goldman and Richard M. Stone and Francisco Cervantes and Andreas Hochhaus and Bayard L. Powell and Janice Gabrilove and Philippe Rousselot and Josy Reiffers and Jan J Cornelissen and Timothy P. Hughes and Hermine Agis and Thomas J. Fischer and Gregor E. G. Verhoef and John D. Shepherd and Giuseppe Saglio and Alois Gratwohl and Johan Lanng Nielsen and Jerald P Radich and Bengt Simonsson and Kerry E. Taylor and Michele Baccarani and Charlene So and Laurie Letvak and Richard A. Larson},
  journal={The New England journal of medicine},
  year={2006},
  volume={355 23},
  pages={
          2408-17
        }
}
BACKGROUND The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy. METHODS We randomly assigned 553 patients to receive imatinib and 553 to receive interferon alfa plus cytarabine and then evaluated them for overall and… 

Figures and Tables from this paper

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
TLDR
During the sixth year of study treatment, there were no reports of disease progression to accelerated phase (AP) or blast crisis (BC), and the toxicity profile was unchanged.
Long‐Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
TLDR
Almost 11 years of follow-up showed that the efficacy of Imatinib persisted over time and that long‐term administration of imatinib was not associated with unacceptable cumulative or late toxic effects.
Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group
TLDR
The results indicate the benefit of early intervention during imatinib therapy and suggest there is room for improvement in the front line results in chronic-phase chronic myeloid leukemia.
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.
TLDR
Both freedom from progression to AP/BP and overall survival (OS) were associated with cytogenetic response level at 12 months, and no increase in rates of serious adverse events was observed with continuous use of imatinib for up to 6.5 years, compared with earlier time points.
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
TLDR
Since achieving complete cytogenetic response within 12 months has been associated with better long-term, progression-free survival, dasatinib may improve the long- term outcomes among patients with newly diagnosed chronic-phase CML.
[Factors associated with achievement and durability of cytogenetic response in patients with chronic myeloid leukemia treated with imatinib].
TLDR
Patients who early achieve complete and major cytogenetic response as well as those with low and moderate relative risk have a higher rate of achieving and maintaining complete cytogenetics response.
Imatinib Mesylate Therapy in Patients of Chronic Myeloid Leukemia with Philadelphia Chromosome Positive: An Experience from Eastern India
TLDR
Continuous treatment of chronic phase CML with imatinib as initial therapy was found to be safe and able to induce durable responses in a high proportion of patients.
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib
TLDR
The long-term outcome of first-line imatinib was excellent, but all responses and outcomes were inferior in high-risk patients, suggesting that to optimize treatment results, a specific risk-adapted treatment is needed for such patients.
Comparison of long-term outcome of early versus late chronic phase imatinib receivers
TLDR
This study justified the significance of ELN criteria and once again approved the high efficacy of imatinib treatment in chronic phase CML patients.
Ph clone recurrence after imatinib discontinuation for chronic myelogenous leukemia patients who had complete molecular remission.
TLDR
The cytogenetic and molecular outcomes of 7 patients with CML, for whom IM therapy had been discontinued after a CMR, and one factor for relapse was that the duration of molecular remission before IM was discontinued was short, suggest discontinuation of IM therapy for patients who have a C MR can not be recommended.
...
...

References

SHOWING 1-10 OF 40 REFERENCES
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
TLDR
Imatinib was superior to interferon alfa plus low-dose cytarabine as first-line therapy in newly diagnosed chronic-phase CML and was better tolerated than combination therapy.
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
TLDR
Imatinib induced high rates of cytogenetic and hematologic responses in patients with chronic-phase CML in whom previous interferon therapy had failed, and CML had not progressed to the accelerated or blast phases after a median follow-up of 18 months.
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
TLDR
It is demonstrated that imatinib has substantial activity and a favorable safety profile when used as a single agent in patients with CML in blast crisis and additional clinical studies are warranted to explore the efficacy and feasibility of imatinIB used in combination with other antileukemic drugs.
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
TLDR
Orally administered imatinib is an effective and well-tolerated treatment for patients with CML in accelerated phase, and a daily dose of 600 mg is more effective than 400 mg, with similar toxicity.
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
TLDR
The proportion of patients with CML who had a reduction in BCR-ABL transcript levels of at least 3 log by 12 months of therapy was far greater with imatinib treatment than with treatment with interferon plus cytarabine.
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
TLDR
Dasatinib induces hematologic and cytogenetic responses in patients with CML or Ph-positive ALL who cannot tolerate or are resistant to imatinib, which is effective in Philadelphia chromosome-positive leukemias but relapse occurs.
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.
TLDR
It is hypothesized that relapses observed within 6 months reflect the kinetics of undetectable dividing chronic myelogenous leukemia (CML) cells, which may be eradicated or controlled in long-term nonrelapsing patients, as described in the study.
Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials.
TLDR
There is a survival advantage from first-line therapy with imatinib over IFN/Ara-C over interferon plus cytarabine, and improved overall survival was also confirmed within different Sokal prognostic risk groups.
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
TLDR
STI571 is well tolerated and has significant antileukemic activity in patients with CML in whom treatment with interferon alfa had failed and demonstrates the potential for the development of anticancer drugs based on the specific molecular abnormality present in a human cancer.
Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation.
TLDR
4 patients with undetectable levels of BCR-ABL transcripts in whom IM therapy was discontinued and two patients relapsed after 7 and 10 months and promptly responded after restarting therapy.
...
...